We are excited to support the 3rd Australian and New Zealand MND Australia Research Symposium, especially as we continue to develop #SPG302 as a potential treatment for #SynapticRegeneration in diseases such as #ALS. This unique event underscores the importance of our work in pioneering first-in-class therapeutics that aim to improve the lives of patients worldwide. Learn more: https://lnkd.in/gjV9NGUb
Spinogenix, Inc.
Biotechnology Research
Los Angeles, California 855 followers
Developing a new class of therapeutics for neurodegenerative and psychiatric diseases
About us
Who we are In most neurodegenerative diseases we lose connections - synapses – between neurons, a process that contributes to declines in cognition and motor function that characterize these diseases. At Spinogenix we are developing first-in-class, novel small molecule drugs (SPGs) that restore synapses to improve and potentially restore cognitive and motor function. Our approach is unique for diseases of the central nervous system. Mission Our mission is to create transformative therapeutics for diseases involving synaptic loss and dysfunction. Our approach is focused on regenerating synapses to reverse declines in cognitive and motor function. This approach is unique among the many therapeutics that are being developed for neurodegenerative conditions, which mostly aim to slow the degenerative process. We envision the use of SPGs as a monotherapy or in combination with other therapeutics that target disease-specific degenerative processes. Our Science In contrast to much research focused on alleviating the symptoms of neurodegenerative disease, we seek to develop therapies that impact the underlying disease and fundamentally change treatment paradigms by restoring neuronal connections regardless of the underlying cause of synapse loss. Spinogenix has discovered compounds (SPGs) that restore lost synapses. We have demonstrated the effectiveness of these “spinogenic” molecules in cells and in multiple animal models of neurodegeneration. SPGs have a novel molecular target and their mechanism of action is well understood and unique. This mechanism would be operative in all diseases where synapse loss occurs, irrespective of the pathological basis of synapse loss.
- Website
-
http://spinogenix.com/
External link for Spinogenix, Inc.
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Los Angeles, California
- Type
- Privately Held
- Founded
- 2016
- Specialties
- Therapeutics, Neurodegeneration, Amyloids, Neurorestorative, ALS, Schizophrenia, Depression, Alzheimer's, Parkinson's, and Synapses
Locations
-
Primary
Get directions
1901 Avenue of the Stars
Los Angeles, California 90067, US
Employees at Spinogenix, Inc.
Updates
-
Thank you to the Herald Sun for sharing the potential impact of our new human clinical trial to treat #AlzheimersDisease with our novel once-a-day pill. We look forward to helping the #PatientCommunity with our new drug candidate targeting the synapses. Read more below.
-
-
Stella Sarraf, PhD just returned from a productive visit to Australia as part of her effort to drive awareness of our clinical trials. We launched our Phase 2 #Alzheimer's (AD) trials this month. A big thank you to all our doctors and patients involved in our potential game-changer treatment for both AD and ALS. #hope #patientsfirst #clinicaltrials #alzheimersawareness
🌏 Reflecting on my recent trip to Australia, I'm filled with a profound sense of gratitude and hope. Our efforts to advance a novel treatment for #AlzheimersDisease (AD) with our #ClinicalTrials is providing a new option for people. Working with a team of caring and motivated gladiator physicians and witnessing their dedication to helping their AD patients has been truly inspiring. This journey has reinforced our commitment to continuing to push the boundaries of research and bringing renewed hope to those affected by this challenging condition. Together, we are making a difference. 🇦🇺🧠✨
-
Our CEO and Founder, Stella Sarraf, PhD, joined Sky News Business Editor Ross Greenwood to discuss the potential of our #AlzheimersDisease and #ALS therapeutic. Listen to the interview to learn more about clinical trial progress in Australia of #SPG302: https://lnkd.in/e8GYUXRs
-
-
Thank you 7NEWS Australia for highlighting our ongoing Phase 2 clinical trial evaluating #SPG302 for the treatment of #AlzheimersDisease in Australia. SPG302 has the potential to be a game-changer by #RegeneratingSynapses to repair damage and recover memory, instead of just slowing disease progression. As a once-a-day pill, Spinogenix aims to provide an effective, patient-friendly solution for those battling this disease. Watch the story here: https://lnkd.in/ekjBahsw #7NEWS
Sydney Alzheimer's patients will be the first to trial a new drug | 7NEWS
https://www.youtube.com/
-
🌟 We are thrilled to announce that our Phase 2 trial evaluating #SPG302 for the treatment of #AlzheimersDisease is open for enrollment in Australia! #SPG302 is a once-a-day pill designed to regenerate synapses and reverse cognitive decline in Alzheimer’s. As Dr. Bruce Brew, the trial's Principal Investigator, stated: "This is a refreshing, long-awaited and cutting-edge approach to the disease, if it’s successful, it could be the dawn of a new era in treating Alzheimer’s disease." At Spinogenix, we are dedicated to developing first-in-class therapies that restore synapses, offering renewed hope for those affected by conditions involving #SynapseLoss and dysfunction. Read more here: https://lnkd.in/gYYsXxkJ
-
-
As National #FragileX Month comes to an end, our commitment to the #FragileXCommunity doesn’t stop. Read our most recent #BlogPost to learn more about our commitment to advancing research and treatment options, which we hope will help people with FXS live better-quality lives: https://lnkd.in/gZM_R568
-
-
Spinogenix is proud to be a sponsor of the International #FragileX Conference this year! Our Chief Medical Advisor, Craig Erickson, MD, is joining the National Fragile X Foundation at the conference, where he is participating in multiple panels and presentations on advancements in #FXS. Learn more: https://lnkd.in/gMQzPHGa
-
-
Exciting news! Enrollment is now open for our Phase 2 clinical trial of #SPG601 in #FragileXSyndrome, the leading inherited form of intellectual disability and a known cause of autism. SPG601 has the potential to address core symptoms of FXS by correcting specific synaptic dysfunctions in the brain. We're committed to pioneering first-in-class therapeutics that #RestoreSynapses and improve lives. 🌟 Read more about this milestone here: https://lnkd.in/gXzSybZ6
-
-
🌍 Today, on #WorldFragileXDay, we join FRAXA Research Foundation and reaffirm our commitment to advancing the understanding & treatment of #FragileXSyndrome. Our #ClinicalTrial of #SPG601 aims to improve the lives of those affected. Learn more here: https://lnkd.in/gWBXgfmC